KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC).
暂无分享，去创建一个
M. Climent | M. Atkins | V. Matveev | F. Pouliot | P. Tomczak | B. Alekseev | F. Donskov | D. McDermott | C. Suarez | Jae-Lyun Lee | R. Perini | S. Shin | P. Wiechno | R. Silverman | M. Ziobro | R. Gafanov | C. Schloss